Fig. 1

Oncolysis with GLV-1 h68. SRB viability assays employing oncolytic vaccinia virus vector GLV-1 h68 on the NET/NEC cell line panel of six different tumor cell lines originating from different neuroendocrine neoplasms. Lung NET cell lines are shown in the upper panel (a, b), pancreatic NET cell lines in the middle (c, d), and intestinal NEC cell lines in the lower panel (e, f). Analysis was performed at 96 hpi. H727, BON-1 and HROC-57 cells were found to be highly permissive; UMC-11, QGP-1, and NEC-DUE1 cells were classified as permissive. BON-1 cells exhibited a quite strong response, requiring only MOI 0.01 to reach the threshold of 60% remaining tumor cells. Four independent experiments (six for UMC-11 cells) were carried out in quadruplicates; bars show mean and SD. The lowest MOI being significantly superior to mock treatment is indicated with * p < 0.01 or ** p < 0.001. Higher MOIs of the same cell line were also found to be significantly superior to mock treatment